Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formulations

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7022-7031

  Kanakia, Shruti ^a   Toussaint, Jimmy D ^a   Mullick Chowdhury, Sayan ^a   Tembulkar, Tanuf ^a   Lee, Stephen ^a   Jiang, Ya Ping ^b   Lin, Richard Z ^b   Shroyer, Kenneth R ^c   Moore, William ^c   Sitharaman, Balaji ^a  

^a St Francis Hospital The Heart Center   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Biodistribution; Dextran; Dose range; Graphene nanoplatelets; Maximum tolerated dose; Toxicity

Indexed keywords

BLOOD; DEXTRAN; GRAPHENE; MEDICAL APPLICATIONS; NANOPARTICLES;

BIODISTRIBUTIONS; CARDIOVASCULAR PARAMETERS; DOSE RANGE; GRAPHENE NANOPLATELETS; INVESTIGATIONAL NEW DRUGS; MAXIMUM TOLERATED DOSE; NANO-PARTICLE DISPERSIONS; NANOPARTICLE FORMULATION;

TOXICITY;

DEXTRAN; GRAPHENE OXIDE; MANNITOL; NANOPARTICLE; BIOMATERIAL; GRAPHITE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD FLOW VELOCITY; BLOOD PRESSURE MEASUREMENT; BREATHING RATE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SCREENING; ERYTHROCYTE; GOOD LABORATORY PRACTICE; HEART EJECTION FRACTION; HEART RATE; HEMATOCRIT; HISTOPATHOLOGY; KIDNEY FUNCTION; LEUKOCYTE; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TOXICOKINETICS; TRANSTHORACIC ECHOCARDIOGRAPHY; ANIMAL; CHEMISTRY; DRUG EFFECTS; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; LUNG; METABOLISM; SPLEEN; TOXICITY TESTING; WISTAR RAT;

RATTUS;

ADMINISTRATION, INTRAVENOUS; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; DEXTRANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GRAPHITE; HALF-LIFE; KIDNEY; LIVER; LUNG; MALE; MAXIMUM TOLERATED DOSE; NANOPARTICLES; RATS; RATS, WISTAR; SPLEEN; TOXICITY TESTS, ACUTE;

EID: 84902080080     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.066     Document Type: Article

References (52)

1. Nakamura E., Isobe H. Functionalized fullerenes in water. The first 10 years of their chemistry, biology, and nanoscience. Acc Chem Res 2003, 36:807-815.
2. Liu Z., Tabakman S., Welsher K., Dai H.J. Carbon nanotubes in biology and medicine: invitro and invivo detection, imaging and drug delivery. Nano Res 2009, 2:85-120.
3. Lalwani G., Sitharaman B. Multifunctional fullerene- and metallofullerene-based nanobiomaterials. Nano Life 2013, 3:1342003.
4. Sun X., Liu Z., Welsher K., Robinson J.T., Goodwin A., Zaric S., et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 2008, 1:203-212.
5. Liu Z., Robinson J.T., Sun X., Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. JAm Chem Soc 2008, 130:10876-10877.
6. Yang X., Zhang X., Liu Z., Ma Y., Huang Y., Chen Y. High-efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide. JPhys Chem C 2008, 112:17554-17558.
7. Feng L., Zhang S., Liu Z. Graphene based gene transfection. Nanoscale 2011, 3:1252-1257.
8. Paratala B.S., Jacobson B.D., Kanakia S., Francis L.D., Sitharaman B. Physicochemical characterization, and relaxometry studies of micro-graphite oxide, graphene nanoplatelets, and nanoribbons. PLoS One 2012, 7:e38185.
9. Kanakia S., Toussaint J.D., Chowdhury S.M., Lalwani G., Tembulkar T., Button T., Shroyer K., et al. Physicochemical characterization of a novel graphene based magnetic resonance imaging contrast agent. Int J Nanomed 2013, 8:2821-2833.
10. Lalwani G., Sundararaj J.L., Schaefer K., Button T., Sitharaman B. Synthesis, characterization, invitro phantom imaging, and cytotoxicity of a novel graphene-based multimodal magnetic resonance imaging - X-ray computed tomography contrast agent. JMat Chem. B 2014, Advance Article. 10.1039/C4TB00326H.
11. Lalwani G., Cai X., Nie L., Wang L.V., Sitharaman B. Graphene-based contrast agents for photoacoustic and thermoacoustic tomography. Photoacoustics 2013, 1:62-67.
12. Lacerda L., Bianco A., Prato M., Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev 2006, 58:1460-1470.
13. Poland C.A., Duffin R., Kinloch I., Maynard A., Wallace W.A., Seaton A., et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 2008, 3:423-428.
14. Colvin V.L. The potential environmental impact of engineered nanomaterials. Nat Biotechnol 2003, 21:1166-1170.
15. Feng L., Liu Z. Graphene in biomedicine: opportunities and challenges. Nanomedicine (Lond) 2011, 6:317-324.
16. Kolosnjaj-Tabi J., Hartman K.B., Boudjemaa S., Ananta J.S., Morgant G., Szwarc H., et al. Invivo behavior of large doses of ultrashort and full-length single-walled carbon nanotubes after oral and intraperitoneal administration to swiss mice. ACS Nano 2010, 4:1481-1492.
17. Lacerda L., Herrero M.A., Venner K., Bianco A., Prato M., Kostarelos K. Carbon-nanotube shape and individualization critical for renal excretion. Small 2008, 4:1130-1132.
18. Kostarelos K., Bianco A., Prato M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat Nanotechnol 2009, 4:627-633.
19. Singh S.K., Singh M.K., Nayak M.K., Kumari S., Shrivastava S., Gracio J.A., et al. Thrombus inducing property of atomically thin graphene oxide sheets. ACS Nano 2011, 5:4987-4996.
20. Chang Y., Yang S.-T., Liu J.-H., Dong E., Wang Y., Cao A., et al. Invitro toxicity evaluation of graphene oxide on A549 cells. Toxicol Lett 2011, 200:201-210.
21. Sasidharan A., Panchakarla L.S., Chandran P., Menon D., Nair S., Rao C.N.R., et al. Differential nano-bio interactions and toxicity effects of pristine versus functionalized graphene. Nanoscale 2011, 3:2461-2464.
22. Yang K., Gong H., Shi X., Wan J., Zhang Y., Liu Z. Invivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration. Biomaterials 2013, 34:2787-2795.
23. Zhang S., Yang K., Feng L., Liu Z. Invitro and invivo behaviors of dextran functionalized graphene. Carbon 2011, 49:4040-4049.
24. Zhang X., Yin J., Peng C., Hu W., Zhu Z., Li W., et al. Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration. Carbon 2011, 49:986-995.
25. Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., et al. Invivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007, 2:47-52.
26. Diehl K.H., Hull R., Morton D., Pfister R., Rabemampianina Y., Smith D., et al. Agood practice guide to the administration of substances and removal of blood, including routes and volumes. JAppl Toxicol 2001, 21:15-23.
27. Wang K., Ruan J., Song H., Zhang J., Wo Y., Guo S., et al. Biocompatibility of graphene oxide. Nanoscale Res Lett 2011, 6:8.
28. Yang K., Wan J., Zhang S., Zhang Y., Lee S.-T., Liu Z. Invivo pharmacokinetics, long-term biodistribution, and toxicology of pegylated graphene in mice. ACS Nano 2011, 5:516-522.
29. ICH guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies s3a. http://wwwichorg/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S3A/Step4/S3A_Guidelinepdf1994.
30. OECD guidelines for the testing of the chemicals-draft proposal for a revised TG 417: Toxicokinetics. http://wwwoecdorg/env/ehs/testing/41690691pdf2008.
31. M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. http://www.fda.gov/RegulatoryInformation/Guidances/ucm129520.htm2010.
32. Guidance for industry, developing medical imaging drug and biological products, part 1: conducting safety assessments 2004, Center for Drug Evaluation and Research, Food and Drug Administration. http://wwwfdagov/cber/guidelineshtm.
33. Kim Y.-K., Kim M.-H., Min D.-H. Biocompatible reduced graphene oxide prepared by using dextran as a multifunctional reducing agent. Chem Commun 2011, 47:3195-3197.
34. Shan C., Yang H., Han D., Zhang Q., Ivaska A., Niu L. Water-soluble graphene covalently functionalized by biocompatible poly-l-lysine. Langmuir 2009, 25:12030-12033.
35. Murabito J.M., D'Agostino R.B., Silbershatz H., Wilson W.F. Intermittent claudication. A risk profile from the framingham heart study. Circulation 1997, 96:44-49.
36. Baseline hematology and clinical chemistry values for charles river wistar rats. http://wwwcrivercom/files/pdfs/rms/wistar-rats/rm_rm_r_hematology_crl_wi_br_sex_age1998.
37. Krystek P. Areview on approaches to bio distribution studies about gold and silver engineered nanoparticles by inductively coupled plasma mass spectrometry. Microchem J 2012, 105:39-43.
38. Staszyk C., Bohnet W., Gasse H., Hackbarth H. Blood vessels of the rat tail: a histological re-examination with respect to blood vessel puncture methods. Lab Anim 2003, 37:121-125.
39. Inoue K. Promoting effects of nanoparticles/materials on sensitive lung inflammatory diseases. Environ Health Prev Med 2011, 16:139-143.
40. Song Y., Li X., Du X. Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur Respir J 2009, 34:559-567.
41. Phillips J.I., Green F.Y., Davies J.C., Murray J. Pulmonary and systemic toxicity following exposure to nickel nanoparticles. Am J Ind Med 2010, 53:763-767.
42. Li N., Xia T., Nel A.E. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic Biol Med 2008, 44:1689-1699.
43. Tabuchi A., Mertens M., Kuppe H., Pries A.R., Kuebler W.M. Intravital microscopy of the murine pulmonary microcirculation. JAppl Physiol (1985) 2008, 104:338-346.
44. Panich A.M., Shames A.I., Sergeev N.A. Paramagnetic impurities in graphene oxide. Appl Magn Reson 2013, 44:107-116.
45. Panich A.M., Shames A.I., Aleksenskii A.E., Dideikin A. Magnetic resonance evidence of manganese-graphene complexes in reduced graphene oxide. Solid State Commun 2012, 152:466-468.
46. Lee L.-W., So P.-W., Price A.N., Parkinson J.R.C., Larkman D.J., Halliday J., et al. Manganese enhancement in non-CNS organs. NMR Biomed 2010, 23:931-938.
47. 2. Acta Radiol 1997, 38:700-707.
48. Nishikawa M., Staud F., Takemura S., Takakura Y., Hashida M. Pharmacokinetic evaluation of biodistribution data obtained with radiolabeled proteins in mice. Biol Pharm Bull 1999, 22:214-218.
49. Vexler V.S., Clément O., Schmitt-Willich H., Brasch R.C. Effect of varying the molecular weight of the MR contrast agent Gd-DTPA-polylysine on blood pharmacokinetics and enhancement patterns. JMagn Reson Imaging 1994, 4:381-388.
50. Sperling F., McLaughlin J.L. Biological parameters and the acute LD50 test. JAssoc Off Anal Chem 1976, 59:734-736.
51. Zbinden G., Flury-Roversi M. Significance of the LD50-test for the toxicological evaluation of chemical substances. Arch Toxicol 1981, 47:77-99.
52. Chowdhury S.M., Kanakia S., Toussaint J.D., Frame M.D., Dewar A.M., Shroyer K.R., et al. Invitro hematological and invivo vasoactivity assessment of dextran functionalized graphene. Sci Rep 2013, 3.